[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Aurinia Pharmaceuticals Inc.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":69},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,44],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100643458","phase-4-preserve-lupkynis-in-combination-with-belimumab-obinutuzumab-or-anifrolumab-in-patients-with-lupus-nephritis-100643458",false,"NCT07611214","PRESERVE: LUPKYNIS in Combination With Belimumab, Obinutuzumab or Anifrolumab in Patients With Lupus Nephritis","PRESERVE: A Multi-Center Phase 4 Study of the Efficacy and Safety of LUPKYNIS in Combination With Belimumab, Obinutuzumab or Anifrolumab at Inducing Rapid Renal Response in Patients With Lupus Nephritis","Key Inclusion Criteria:\n\n* Adults 18-75 years old\n* Diagnosed with biopsy-proven lupus nephritis (LN) according to the 2003 International Society of Nephrology (ISN) \u002F Renal Pathology Society (RPS) (class III, class IV, class III\u002FV or class IV\u002FV)\n* Urine protein-to-creatine ratio (UPCR) ≥0.5 g\u002Fg and \\\u003C5.0 g\u002Fg from a first morning void (FMV) urine sample\n* Estimated glomerular filtration rate (eGFR) of ≥45 mL\u002Fmin\u002F1.73 m2\n* Concomitant biologic:\n\n  * Patients on the belimumab or anifrolumab treatment regimens are receiving belimumab or anifrolumab (as applicable) prior to Screening or will initiate belimumab or anifrolumab (as applicable) on or before Day 1.\n  * Patients on the obinutuzumab treatment regimen must have received at least 2 administrations of obinutuzumab prior to Screening.\n* Willing to take mycophenolic acid analog (MPAA), either by continuing current MPAA therapy or by initiating it on or before Day 1\n* Willing to take corticosteroids, either by continuing current corticosteroids (prednisone \\[or equivalent\\]) or by initiating on or before Day 1\n\nKey Exclusion Criteria:\n\n* Any B cell targeted therapy except for the concomitant biologics (belimumab and obinutuzumab) within 1 year prior to Screening unless demonstration of B cell count within the normal range\n* Cyclophosphamide or any calcineurin inhibitor other than voclosporin (eg, cyclosporine and tacrolimus) within 3 months prior to Screening\n* Any other immunosuppressive therapy except for the concomitant drugs (anifrolumab, MPAAs and oral prednisone \\[or equivalent\\]) and immunosuppressive agents used to treat a patient's underlying systemic lupus erythematosus (SLE), including, but not limited to, the examples below, within 30 days or 5 half-lives, whichever is longer, prior to Screening:\n\n  * Anti-tumor necrosis factor (TNF) therapy (eg, adalimumab, etanercept, infliximab)\n  * Anti-interleukin therapy (eg, risankizumab, secukinumab, ixekizumab, ustekinumab, guselkumab, tocilizumab, dupilumab)\n  * T cell costimulation modulator (eg, abatacept)\n  * Intravenous immunoglobulin (IVIg)\n  * Janus kinase (JAK) inhibitors (eg, upadacitinib)\n* Pregnant, breastfeeding or intending to become pregnant during the Study","ALL","18 Years","75 Years",{"count":20,"type":21},150,"ESTIMATED","INTERVENTIONAL",[24],"PHASE4","The goal of this clinical study is to assess the efficacy and safety of LUPKYNIS® in combination with belimumab, obinutuzumab or anifrolumab at inducing rapid renal response in patients with lupus nephritis (LN).",[27],"Lupus Nephritis",[29,30],"voclosporin","calcineurin inhibitor","RECRUITING","2026-06-11",{"date":34,"type":35},"2026-06-12","ACTUAL",{"date":37,"type":35},"2026-04-22",{"date":39,"type":21},"2029-03-02",{"name":41,"class":42},"Aurinia Pharmaceuticals Inc.","INDUSTRY",15,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":51,"enrollmentInfo":52,"targetDuration":4,"studyType":22,"phases":54,"briefSummary":57,"conditions":58,"keywords":60,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":66,"leadSponsor":67,"locationsCount":68},"100637137","phase-1-study-of-aritinercept-in-patients-with-generalized-myasthenia-gravis-100637137","NCT07596901","Study of Aritinercept in Patients With Generalized Myasthenia Gravis","A Double-Blind, Randomized, Placebo-Controlled Study to Investigate the Safety and Efficacy of Aritinercept, a Dual BAFF\u002FAPRIL Inhibitor, in Patients With Generalized Myasthenia Gravis","Key Inclusion Criteria:\n\n* Adult patients (18-85 years old)\n* Myasthenia Gravis Foundation of America (MGFA) Class II-IV gMG\n* Additional inclusion criteria are defined in the protocol\n\nKey Exclusion Criteria:\n\n* Current or medical history of malignancy within the last 5 years\n* Pregnant, breastfeeding or intending to become pregnant during the Study\n* Additional exclusion criteria are defined in the protocol","85 Years",{"count":53,"type":21},81,[55,56],"PHASE1","PHASE2","This clinical study will enroll patients with generalized myasthenia gravis (gMG). The goal of this clinical study is to assess the safety, tolerability, effectiveness, pharmacokinetics (how the body processes the drug) and pharmacodynamics (how the drug affects the body) of aritinercept.",[59],"Myasthenia Gravis, Generalized",[61],"aritinercept","2026-05-13",{"date":64,"type":35},"2026-05-19",{"date":37,"type":35},{"date":39,"type":21},{"name":41,"class":42},3,""]